

Adilia Warris

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/759056/publications.pdf](https://exaly.com/author-pdf/759056/publications.pdf)

Version: 2024-02-01

70
papers

3,073
citations

245449

24
h-index

175522

52
g-index

75
all docs

75
docs citations

75
times ranked

5111
citing authors

#	ARTICLE	IF	CITATIONS
1	Tackling the emerging threat of antifungal resistance to human health. <i>Nature Reviews Microbiology</i> , 2022, 20, 557-571.	29.2	430
2	Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. <i>Lancet Oncology</i> , The, 2014, 15, e327-e340.	10.8	332
3	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015, 21-22, 30-40.	14.6	266
4	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e246-e257.	8.9	205
5	Epidemiology of Invasive Fungal Disease in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S3-S11.	1.2	159
6	8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. <i>Lancet Oncology</i> , The, 2021, 22, e254-e269.	10.8	109
7	Population genomics confirms acquisition of drug-resistant <i>Aspergillus fumigatus</i> infection by humans from the environment. <i>Nature Microbiology</i> , 2022, 7, 663-674.	13.1	108
8	Ibrutinib blocks Btk-dependent NF- κ B and NFAT responses in human macrophages during <i>Aspergillus fumigatus</i> phagocytosis. <i>Blood</i> , 2018, 132, 1985-1988.	1.4	98
9	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. <i>Microbial Cell</i> , 2018, 5, 300-326.	3.1	89
10	In-host microevolution of <i>Aspergillus fumigatus</i> : A phenotypic and genotypic analysis. <i>Fungal Genetics and Biology</i> , 2018, 113, 1-13.	2.2	82
11	8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. <i>Lancet Oncology</i> , The, 2021, 22, e270-e280.	10.8	80
12	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3205-3216.	15.4	75
13	Pathogenesis of Respiratory Viral and Fungal Coinfections. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0009421.	14.4	73
14	Etiology and Outcome of Candidemia in Neonates and Children in Europe. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 114-120.	2.0	71
15	Oxidative responses and fungal infection biology. <i>Seminars in Cell and Developmental Biology</i> , 2019, 89, 34-46.	5.4	70
16	<i>Aspergillus</i> infections in cystic fibrosis. <i>Journal of Infection</i> , 2016, 72, S50-S55.	3.4	67
17	ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. <i>European Respiratory Review</i> , 2015, 24, 565-581.	7.4	59
18	<i>Aspergillosis</i> in Chronic Granulomatous Disease. <i>Journal of Fungi (Basel, Switzerland)</i> , 2016, 2, 15.	3.6	53

#	ARTICLE	IF	CITATIONS
19	Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S12-S21.	1.2	49
20	The role of the multidisciplinary team in antifungal stewardship. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, ii37-ii42.	3.2	41
21	The biology of pulmonary aspergillus infections. <i>Journal of Infection</i> , 2014, 69, S36-S41.	3.4	38
22	<i>Aspergillus</i> colonization and antifungal immunity in cystic fibrosis patients. <i>Medical Mycology</i> , 2019, 57, S118-S126.	0.8	38
23	Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. <i>PLoS ONE</i> , 2020, 15, e0229380.	2.5	38
24	Recognition and diagnosis of invasive fungal infections in neonates. <i>Journal of Infection</i> , 2017, 74, S108-S113.	3.4	30
25	Management of Invasive Fungal Disease in Neonates and Children. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, S2-S6.	2.0	27
26	Recreation of in-host acquired single nucleotide polymorphisms by CRISPR-Cas9 reveals an uncharacterised gene playing a role in <i>Aspergillus fumigatus</i> azole resistance via a non-cyp51A mediated resistance mechanism. <i>Fungal Genetics and Biology</i> , 2019, 130, 98-106.	2.2	26
27	Pulmonary and Extrapulmonary Manifestations of Fungal Infections Misdiagnosed as Tuberculosis: The Need for Prompt Diagnosis and Management. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 460.	3.6	26
28	Mitochondrial Reactive Oxygen Species Regulate Immune Responses of Macrophages to <i>Aspergillus fumigatus</i> . <i>Frontiers in Immunology</i> , 2021, 12, 641495.	4.9	21
29	Azole-resistant aspergillosis. <i>Journal of Infection</i> , 2015, 71, S121-S125.	3.4	19
30	Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. <i>Medical Mycology</i> , 2019, 57, 937-943.	0.8	18
31	<i>Aspergillus fumigatus</i> tryptophan metabolic route differently affects host immunity. <i>Cell Reports</i> , 2021, 34, 108673.	6.3	18
32	Antifungal Activity of Antimicrobial Peptides and Proteins against <i>Aspergillus fumigatus</i> . <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 65.	3.6	18
33	Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to <i>A. fumigatus</i> . <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	16
34	CFTR Modulators Dampen <i>Aspergillus</i> -Induced Reactive Oxygen Species Production by Cystic Fibrosis Phagocytes. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 372.	4.0	16
35	<i>Aspergillus</i> -induced superoxide production by cystic fibrosis phagocytes is associated with disease severity. <i>ERJ Open Research</i> , 2018, 4, 00068-2017.	2.7	14
36	Paediatric Histoplasmosis 2000-2019: A Review of 83 Cases. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 448.	3.6	14

#	ARTICLE	IF	CITATIONS
37	Population genetics and microevolution of clinical <i>Candida glabrata</i> reveals recombinant sequence types and hyper-variation within mitochondrial genomes, virulence genes, and drug targets. <i>Genetics</i> , 2022, 221, .	2.9	14
38	Progress in the Diagnosis of Invasive Fungal Disease in Children. <i>Current Fungal Infection Reports</i> , 2017, 11, 35-44.	2.5	13
39	The European Paediatric Mycology Network (EPMyn): Towards a Better Understanding and Management of Fungal Infections in Children. <i>Current Fungal Infection Reports</i> , 2016, 10, 7-9.	2.5	12
40	Pediatric Antifungal Prescribing Patterns Identify Significant Opportunities to Rationalize Antifungal Use in Children. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, e69-e74.	2.0	12
41	Evaluating the Sources of Graphene's Resistivity Using Differential Conductance. <i>Scientific Reports</i> , 2017, 7, 10317.	3.4	9
42	Global Divergence of Antifungal Prescribing Patterns. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 327-332.	2.0	9
43	Antifungal Exposure and Resistance Development: Defining Minimal Selective Antifungal Concentrations and Testing Methodologies. <i>Frontiers in Fungal Biology</i> , 0, 3, .	2.1	9
44	First confirmed occurrence of the yellow fever virus and dengue virus vector <i>Aedes (Stegomyia) luteocephalus</i> (Newstead, 1907) in Mozambique. <i>Parasites and Vectors</i> , 2020, 13, 350.	2.6	8
45	Invasive Fungal Infections in the Child with Chronic Granulomatous Disease. <i>Current Fungal Infection Reports</i> , 2014, 8, 37-44.	2.5	7
46	Ataxia telangiectasia: why should the ERS care?. <i>European Respiratory Journal</i> , 2015, 46, 1557-1560.	7.5	7
47	Immunopathology of <i>Aspergillus</i> Infections in Children With Chronic Granulomatous Disease and Cystic Fibrosis. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, e96-e98.	2.0	7
48	Serum Beta-D-Glucan in the Diagnosis of Invasive Fungal Disease in Neonates, Children and Adolescents: A Critical Analysis of Current Data. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 1262.	3.6	7
49	Gastrointestinal Histoplasmosis: A Descriptive Review, 2001–2021. <i>Life</i> , 2023, 13, 689.	2.5	7
50	Prophylactic antibiotics should be used in children with repaired oesophageal atresia and tracheo-oesophageal fistula: The case against. <i>Paediatric Respiratory Reviews</i> , 2016, 18, 62-63.	1.9	6
51	<i>Aspergillus</i> -related lung disease in people with cystic fibrosis: can imaging help us to diagnose disease?. <i>European Respiratory Review</i> , 2021, 30, 210103.	7.4	6
52	Forensic Technology for Source Camera Identification. <i>Communications in Computer and Information Science</i> , 2020, , 466-477.	0.0	4
53	A new paediatric formulation of valaciclovir: development and bioequivalence assessment. <i>Archives of Disease in Childhood</i> , 2016, 101, 971-972.	2.8	3
54	Cryptococcal meningitis after ART: Need for proper baseline evaluation in the era of "Test & Treat". <i>Medical Mycology Case Reports</i> , 2019, 24, 58-60.	1.3	3

#	ARTICLE	IF	CITATIONS
55	Editorial MMCR special issue "Covid-19 associated pulmonary aspergillosis"™. <i>Medical Mycology Case Reports</i> , 2021, 31, 1.	1.3	3
56	Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccination. <i>Heliyon</i> , 2023, 9, e15241.	3.3	3
57	Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim?. <i>Breathe</i> , 2021, 17, 210056.	1.4	2
58	1162. Antifungal Use in Immunocompromised Children in Europe: a 12-week Multicenter Modified Point prevalence Study (CALYPSO). <i>Open Forum Infectious Diseases</i> , 2021, 8, S672-S673.	0.9	2
59	Refractory severe intestinal vasculitis due to Henoch-Schönlein Purpura: successful treatment with plasmapheresis. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2006, 95, 622-623.	1.5	1
60	Serial (1-3)-beta-D-Glucan (BDG) monitoring shows high variability among premature neonates. <i>Medical Mycology</i> , 2022, 60, .	0.8	1
61	An Overview of Systematic Reviews of Polymerase Chain Reaction (PCR) for the Diagnosis of Invasive Aspergillosis in Immunocompromised People: A Report of the Fungal PCR Initiative (FPCRI) An ISHAM Working Group. <i>Journal of Fungi (Basel, Switzerland)</i> , 2023, 9, 967.	3.6	1
62	Pediatric Cryptococcosis. <i>Pediatric Infectious Disease Journal</i> , 2024, 43, 307-312.	2.0	1
63	Antifungal therapy for chronic pulmonary aspergillosis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 924-926.	8.9	0
64	A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA. <i>Journal of Cystic Fibrosis</i> , 2024, 23, 354-363.	0.6	0
65	Bacille Calmette-Guérin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial. <i>EClinicalMedicine</i> , 2024, 72, 102616.	7.2	0
66	Accelerated Bacille Calmette-Guérin reactions: More than meets the eye. <i>Heliyon</i> , 2024, 10, e32510.	3.3	0
67	The pathobiology of human fungal infections. <i>Nature Reviews Microbiology</i> , 0, , .	29.2	0
68	BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial. <i>Journal of Infection</i> , 2024, , 106245.	3.4	0
69	Long-Term Outcomes of Allergic Bronchopulmonary Aspergillosis and Aspergillus Colonization in Children and Adolescents with Cystic Fibrosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2024, 10, 599.	3.6	0
70	The impact of the COVID-19 pandemic and the changing landscape of CF on the cASPerCF trial: a real-world experience. <i>Trials</i> , 2024, 25, .	1.7	0